United States

ReCode Therapeutics is a genetic medicines company that uses a next-generation, selective organ targeting (SORT) lipid nanoparticle (LNP) platform to deliver mRNA and gene correction therapeutics to target organs and cells beyond the liver. Their lead programs focus on primary ciliary dyskinesia and cystic fibrosis, and they are expanding their pipeline with therapeutics that use mRNA-mediated replacement and gene correction in target organs with precision targeting of disease-relevant cells.

Google

Gestor de producte

Científic de dades

ReCode Therapeutics

ReCode Therapeutics Feines Obertes

Estàs preparat per fer un salt en la teva carrera? Revisa aquests llocs oberts a ReCode Therapeutics.